HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.
The only producer of quality-controlled redox variants of HMGB1
Featured news
Has been underscored HMGB1's potential as a strategic target for therapeutic intervention in chronic kidney diseases (CKD).
Among others, HMGB1 protein has been identified for its significant role in the pathology of autism and neurological conditions.
HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.
Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…
Disulfide HMGB1
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…
Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…
From our LinkedIn profile
Featured Products
About us
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…